The therapy for urogenital tuberculosis

Year 2023, , 377 - 382, 29.09.2023

Ekaterina Kulchavenya Mete Çek

https://doi.org/10.5472/marumj.1368375

Cited By: 1

Abstract

Tuberculosis (TB) is a communicable disease that is a major cause of ill health. Urogenital TB was a frequent urological disease in the
pre-antibiotic era: about 20% of patients in urological hospitals had renal TB, mostly in the form of pyonephrosis.
We composed a narrative review of the literature with keywords “urogenital tuberculosis’, “prostate tuberculosis” “kidney tuberculosis”,
“treatment of tuberculosis”.
Urogenital TB (UGTB) includes TB of the kidney and the urinary tract and male and female genital TB. Each clinical presentation
requires tailored antibiotic therapy depending on stage and general management. Anti-TB therapy should be multicomponent,
continuous, long-lasting and controlled with a follow-up for 2-3 years. Otherwise, the risks of development of drug-resistance and
relapse increase.
Index of suspicion on UGTB is generally low, causing a delay in diagnosis; consequently, complicated forms of UGTB respond
poorly to anti-TB therapy, while timely diagnosed “minor” forms are curable medically without surgery. Even with timely diagnosed
UGTB, non-optimal therapy may result in over-fibrosis, scarring and strictures of the urinary tract, making surgical repair inevitable.
Nevertheless, we have a wide enough spectrum of anti-TB drugs to cure urogenital TB.

Keywords

Urogenital tuberculosis, Prostate tuberculosis, Kidney tuberculosis, Prostate tuberculosis, Treatment

References

• Global tuberculosis report 2020. Available on: https://www. who.int/publications/i/item/9789240013131 Accessed on: 12.07.2023
• Stop TB Partnership Civil society-led TB/COVID-19 Working Group. The impact of COVID-19 on the TB epidemic: a community perspective. Geneva, Switzerland: Stop TB Partnership, 2020. Avaliable on: http://www.stoptb.org/assets/documents/resources/ p u b l i c a t i o n s / a c s m / C i v i l % 2 0 Society%20Report%20on%20TB%20and%20COVID. pdf fbclid=IwAR3SOY4kyBs5a_35HIeUhcvwRIW spePA4vVHESqcQxio7G4irivJ90cSU8k. Accessed on: 12.07.2023
• Global tuberculosis report 2021. Available on: https://www. who.int/publications/i/item/9789240037021. Accessed on 12.07.2023
• World Health Organization consoledated guidelines on tuberculosis 2020: module 4: treatment: drug resistant tuberculosis treatment. Available on: https://www.who.int/ publications/i/item/9789240007048. Accessed on 12.07.2023
• Kulchavenya E, Naber K, Bjerklund Johansen TE. Urogenital tuberculosis: classification, diagnosis, and treatm Eur Urol Suppl 2016;15:112-21. doi: 10.1016/j.eursup.2016.04.001
• Kulchavenya E, Kholtobin D, Shevchenko S. Challenges in urogenital tuberculosis. World J Urol 2020 ;38:89-94. doi: 10.1007/s00345-019-02767-x.
• Figueiredo AA, Lucon AM, Srougi M. Urogenital tuberculosis. Microbiol Spectr 2017;5. doi: 10.1128/microbiolspec.TNMI7- 0015-2016.
• Marion G. Traite d’Urologie. Masson, Paris, 1940.
• Kulchavenya E. Urogenital tuberculosis: definition and classification. Ther Adv Infect Dis 2015;2:117-22. doi: 10.1177/2049936115572064.
• Kulchavenya E, Kim CS, Bulanova O, Zhukova I. Male genital tuberculosis: epidemiology and diagnostic. World J Urol 2012;30:15-21. doi: 10.1007/s00345-011-0695-y.
• Stasinou T, Bourdoumis A, Owegie P, Kachrilas S, Buchholz N, Masood J. Calcification of the vas deferens and seminal vesicles: a review. Can J Urol 2015;22:7594-8.
• Elkhachine Y, Sinaa M, Sakkah A, et al. Tuberculose du gland [Tuberculosis of the glans penis]. Ann Dermatol Venereol (French) 2020;147:672-5. doi: 10.1016/j.annder.2020.06.021.
• Banerji JS. Primary tuberculosis of the glans penis in an immunocompetent male. Lancet Infect Dis 2020;20:509. doi: 10.1016/S1473-3099(19)30753-4.
• Sinha RK, Mukherjee S, Kamal MR, Karmakar D. Tuberculosis of the glans penis healing with meatal stenosis. BMJ Case Rep 2014; 5;2014. doi: 10.1136/bcr-2013-202155
• Linden-Castro E, Pelayo-Nieto M, Alias-Melgar A. Penile tuberculosis after intravesical bacille Calmette-Guérin immunotherapy. Urology 2014;84:e3. doi:10.1016/j. urology.2014.04.037.
• Sharma VK, Sethy PK, Dogra PN, Singh U, Das P. Primary tuberculosis of glans penis after intravesical Bacillus Calmette Guerin immunotherapy. Indian J Dermatol Venereol Leprol 2011;77:47-50. doi: 10.4103/0378-6323.74979.
• Krutikov M, Bruchfeld J, Migliori GB, et al. New and repurposed drugs. In: Migliori GB, Bothamley G, Duarte R, et al., eds. Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society, 2018; 179-204 [doi: 10.1183/2312508X.10021517].
• Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis-- advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis 2016;16:e34-46. doi: 10.1016/S1473-3099(16)00070-0.
• Kulchavenya E. Urogenital tuberculosis: epidemiology, diagnosis, therapy. New York: Springer Cham, 2014:137. doi: 10.1007/978-3-319-04837-6
• Kayukova L A, Berikova E A. Modern anti-tuberculosis drugs and their classification. part I: First-line drugs. Pharm Chem J 2020; 54:555-63. doi:10.1007/s11094-020-02239-2
• World Health Organization Library Cataloguing-in- Publication Data: Treatment of tuberculosis: guidelines – 4th ed. Avaiable on: https://apps.who.int/iris/bitstream/handle/10665/44165/9789241547833_eng.pdf ?sequence=1. Accessed on: 12.07.2023
• DR-TB STAT. Country updates. Avaiable on: http://drtb-stat. org/country-updates. Accessed on 12.07.2023
• WHO. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. Geneva: WHO, 2017.
• Lessem E, Low M. The tuberculosis treatment pipeline. In: Claydon P, Collins S, Frick M, et al., eds. 2016 Pipeline Report: HIV and TB, Drugs, Diagnostics, Vaccines, Preventive Technologies, Cure Research, and Immune-based and Gene Therapies in Development. New York: Treatment Action Group, 2016: 129-42.
• Tiberi S, D’Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Migliori GB. Tuberculosis elimination, patients’ lives and rational use of new drugs: revisited. Eur Respir J 2016;47:664- 7. doi: 10.1183/13993003.01297-2015.
• Working Group on New TB Drugs. Clinical pipeline. Available on: www.newtbdrugs.org/pipeline/clinical. Accessed on 12.07.2023
• Li SY, Tasneen R, Tyagi S, et al. Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2017;61:e00913-17. doi: 10.1128/AAC.00913-17.
• Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009;53:1290-2. doi: 10.1128/ AAC.01393-08.
• Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015;19:979-85. doi: 10.5588/ijtld.14.0944.
• Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017;49:1602308. doi: 10.1183/13993003.02308-2016.
• Matteelli A, D’Ambrosio L, Centis R, Tadolini M, Migliori GB. Compassionate and optimum use of new tuberculosis drugs. Lancet Infect Dis 2015;15:1131-2. doi: 10.1016/S1473- 3099(15)00296-0.
• Zahedi Bialvaei A, Rahbar M, Yousefi M, Asgharzadeh M, Samadi Kafil H. Linezolid: a promising option in the treatment of Gram-positives. J Antimicrob Chemother 2017;72:354-64. doi: 10.1093/jac/dkw450.
• Zhang Z, Pang Y, Wang Y, Liu C, Zhao Y. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Agents 2014;43:231-5. doi: 10.1016/j.ijantimicag.2013.12.007.
• Shevchenko SY, Kulchavenya EV, Kholtobin DP. [Method for evaluating the efficiency of treatment of urogenital tuberculosis]. Urologiia (Russian) 2020;(4):10-13.
• Bhat S, Srinivasa Y, Paul F. Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder. Indian J Urol 2015;31:259-61. doi: 10.4103/0970-1591.156921.
• Al-Qaoud T, Brimo F, Aprikian AG, Andonian S. BCG-related renal granulomas managed conservatively: A case series. Can Urol Assoc J 2015;9:E200-3. doi: 10.5489/cuaj.2664.
• Pommier JD, Ben Lasfar N, Van Grunderbeeck N, et al. Complications following intravesical bacillus Calmette- Guerin treatment for bladder cancer: a case series of 22 patients. Infect Dis (Lond) 2015;47:729-35. doi: 10.3109/23744235.2015.1055794.
• Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F et al. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore) 2014;93:236-54. doi:10.1097/ MD.0000000000000119.